These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 21815961)

  • 1. The benefit of cardiac resynchronization therapy and QRS duration: a meta-analysis.
    Stavrakis S; Lazzara R; Thadani U
    J Cardiovasc Electrophysiol; 2012 Feb; 23(2):163-8. PubMed ID: 21815961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy.
    Biton Y; Kutyifa V; Cygankiewicz I; Goldenberg I; Klein H; McNitt S; Polonsky B; Ruwald AC; Ruwald MH; Moss AJ; Zareba W
    Circ Heart Fail; 2016 Feb; 9(2):e002667. PubMed ID: 26823498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block.
    Biton Y; Zareba W; Goldenberg I; Klein H; McNitt S; Polonsky B; Moss AJ; Kutyifa V;
    J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26124205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials.
    Sipahi I; Carrigan TP; Rowland DY; Stambler BS; Fang JC
    Arch Intern Med; 2011 Sep; 171(16):1454-62. PubMed ID: 21670335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac-resynchronization therapy in patients with systolic heart failure and QRS interval ≤130 ms: insights from a meta-analysis.
    Shah RM; Patel D; Molnar J; Ellenbogen KA; Koneru JN
    Europace; 2015 Feb; 17(2):267-73. PubMed ID: 25164431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
    Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
    Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study.
    Hsu JC; Solomon SD; Bourgoun M; McNitt S; Goldenberg I; Klein H; Moss AJ; Foster E;
    J Am Coll Cardiol; 2012 Jun; 59(25):2366-73. PubMed ID: 22698490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality reduction of cardiac resynchronization and implantable cardioverter-defibrillator therapy in heart failure: an updated meta-analysis. Does recent evidence change the standard of care?
    Bertoldi EG; Polanczyk CA; Cunha V; Ziegelmann PK; Beck-da-Silva L; Rohde LE
    J Card Fail; 2011 Oct; 17(10):860-6. PubMed ID: 21962425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute survival after cardiac resynchronization therapy according to baseline QRS duration: a multinational 10-year experience: data from the Multicenter International CRT Study.
    Gasparini M; Leclercq C; Yu CM; Auricchio A; Steinberg JS; Lamp B; Klersy C; Leyva F
    Am Heart J; 2014 Feb; 167(2):203-209.e1. PubMed ID: 24439981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study.
    Gold MR; Thébault C; Linde C; Abraham WT; Gerritse B; Ghio S; St John Sutton M; Daubert JC
    Circulation; 2012 Aug; 126(7):822-9. PubMed ID: 22781424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cardiac resynchronization therapy on patients with heart failure and narrow QRS complexes: a meta-analysis of five randomized controlled trials.
    Wang G; Zhao Z; Zhao S; Ding S; Shen S; Wang L
    J Interv Card Electrophysiol; 2015 Oct; 44(1):71-9. PubMed ID: 26162538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study.
    Linde C; Gold M; Abraham WT; Daubert JC;
    Am Heart J; 2006 Feb; 151(2):288-94. PubMed ID: 16442890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).
    Birnie DH; Ha A; Higginson L; Sidhu K; Green M; Philippon F; Thibault B; Wells G; Tang A
    Circ Heart Fail; 2013 Nov; 6(6):1190-8. PubMed ID: 23995437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized study of cardiac resynchronization therapy defibrillator versus dual-chamber implantable cardioverter-defibrillator in ischemic cardiomyopathy with narrow QRS: the NARROW-CRT study.
    Muto C; Solimene F; Gallo P; Nastasi M; La Rosa C; Calvanese R; Iengo R; Canciello M; Sangiuolo R; Diemberger I; Ciardiello C; Tuccillo B
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):538-45. PubMed ID: 23592833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure.
    Ghali JK; Boehmer J; Feldman AM; Saxon LA; Demarco T; Carson P; Yong P; Galle EG; Leigh J; Ecklund FL; Bristow MR
    J Card Fail; 2007 Nov; 13(9):769-73. PubMed ID: 17996827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QRS axis and the benefit of cardiac resynchronization therapy in patients with mildly symptomatic heart failure enrolled in MADIT-CRT.
    Brenyo A; Rao M; Barsheshet A; Cannom D; Quesada A; McNitt S; Huang DT; Moss AJ; Zareba W
    J Cardiovasc Electrophysiol; 2013 Apr; 24(4):442-8. PubMed ID: 23252875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyssynchrony, contractile function, and response to cardiac resynchronization therapy.
    Knappe D; Pouleur AC; Shah AM; Cheng S; Uno H; Hall WJ; Bourgoun M; Foster E; Zareba W; Goldenberg I; McNitt S; Pfeffer MA; Moss AJ; Solomon SD;
    Circ Heart Fail; 2011 Jul; 4(4):433-40. PubMed ID: 21602574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT).
    Healey JS; Hohnloser SH; Exner DV; Birnie DH; Parkash R; Connolly SJ; Krahn AD; Simpson CS; Thibault B; Basta M; Philippon F; Dorian P; Nair GM; Sivakumaran S; Yetisir E; Wells GA; Tang AS;
    Circ Heart Fail; 2012 Sep; 5(5):566-70. PubMed ID: 22896584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac resynchronization therapy reduces the risk of cardiac events in patients with diabetes enrolled in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT).
    Martin DT; McNitt S; Nesto RW; Rutter MK; Moss AJ
    Circ Heart Fail; 2011 May; 4(3):332-8. PubMed ID: 21350054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).
    Ruwald MH; Ruwald AC; Jons C; Alexis J; McNitt S; Zareba W; Moss AJ
    J Am Coll Cardiol; 2013 Apr; 61(14):1518-26. PubMed ID: 23500269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.